8-K: Sanuwave Hits Record Q3 Revenue, Guides Strong Q4

Sanuwave Health, Inc. announced record third-quarter 2025 revenues of $11.5 million, a 22% increase year-over-year, and provided optimistic Q4 and full-year guidance.

Summary

• Q3 2025 revenues reached a record $11.5 million, a 22% increase from $9.4 million in Q3 2024, and a 13% sequential increase from Q2 2025.
• The company sold 155 UltraMist systems in Q3 2025, an all-time quarterly record, up from 124 in Q3 2024.
• UltraMist consumables revenue increased by 26% to $6.8 million in Q3 2025 compared to $5.4 million in Q3 2024.
• Gross margin for Q3 2025 was 77.9%, up from 75.5% in Q3 2024.
• GAAP Operating Income for Q3 2025 was $1.5 million, down from $2.0 million in Q3 2024, primarily due to $1.4 million in stock-based compensation costs.
• Net income for Q3 2025 was $10.3 million, a significant improvement from a net loss of $20.7 million in Q3 2024, largely driven by a $6.1 million non-cash gain from derivative liabilities and a $5.0 million payment from patent sales.
• Adjusted EBITDA for Q3 2025 was $3.5 million, up from $2.1 million in Q3 2024.
• The company forecasts Q4 2025 revenue of $13-$14 million and full-year 2025 revenue of $44-$45 million, representing 35-39% growth over full year 2024.

Sentiment

Score: 7

Explanation: The company reported record revenues and strong growth, along with improved gross margin and Adjusted EBITDA. Net income saw a significant boost, though largely from non-cash items and a one-time patent sale. Positive future guidance and clarity on key reimbursement codes contribute to a positive outlook, despite a dip in operating income due to stock-based compensation and industry-wide caution during the quarter.

Positives

• Record quarterly revenues of $11.5 million, up 22% year-over-year.
• Highest quarterly sales of UltraMist systems (155 units) in company history.
• 26% increase in UltraMist consumables revenue to $6.8 million.
• Improved gross margin of 77.9% compared to 75.5% in the prior year.
• Significant improvement in net income to $10.3 million from a $20.7 million net loss, aided by non-cash gains and patent sale.
• Adjusted EBITDA increased to $3.5 million from $2.1 million.
• Positive revenue guidance for Q4 2025 ($13-$14 million) and full year 2025 ($44-$45 million, 35-39% growth).
• Clarity from CMS on 2026 Medicare physician fees for code 97610, with a slight increase expected and no negative impact from cuts to other modalities.
• Robust sales pipeline and inbound interest from customers and distribution partners.
• Total Stockholders Deficit improved from $(12.717) million to $(2.931) million.
• Current Liabilities significantly decreased from $42.345 million to $19.577 million.

Negatives

• Q3 2025 revenue of $11.5 million was below the company's initial guidance, though within the preliminary range provided later.
• GAAP Operating Income decreased to $1.5 million from $2.0 million, primarily due to $1.4 million in stock-based compensation costs.
• Net income was significantly boosted by non-cash gains from derivative liabilities ($6.1 million) and a one-time patent sale ($5.0 million), which are not indicative of core operational profitability.
• Lower patient volumes treated by providers suppressed applicator sales, despite being an all-time high.
• Net cash flows provided by operating activities decreased to $557 thousand from $1.714 million year-over-year for the nine months ended September 30.
• Net cash flows used in financing activities significantly increased to $(4.346) million from $(119) thousand for the nine months ended September 30.
• Cash and cash equivalents decreased from $10.237 million at December 31, 2024, to $9.602 million at September 30, 2025.

Risks

• Uncertainty about proposed reimbursement changes to certain wound care modalities, particularly skin substitutes/allografts, which caused industry-wide caution.
• Lower patient volumes treated by providers, which suppressed applicator sales.
• Concerns about compliance and audits leading practitioners to adopt a cautious "wait and see" attitude on initiating advanced wound care regimens.
• Risks associated with regulatory oversight.
• Changes in reimbursement levels for the company's products and related services.
• The company's ability to manage its capital resources.
• Competition within the wound care market.
• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.

Future Outlook

The company forecasts Q4 2025 revenue to be between $13 million and $14 million, and full-year 2025 revenue to be between $44 million and $45 million, which would represent a 35-39% growth compared to full year 2024. Management expresses high optimism about the future, citing robust sales pipeline and inbound interest following clarity on CMS reimbursement rules.

Management Comments

• "Despite the headwinds in the quarter arising from uncertainty about proposed reimbursement changes to certain wound care modalities, particularly skin substitutes/allografts, Sanuwave achieved record revenues in Q3 2025 for both systems and applicators, achieving 22% year on year growth against the difficult comparison of Q3 last year when a large order drove 89% year on year growth."
• "System sales in particular were a bright spot with 155 systems sold in the quarter."
• "Applicator sales were also an all-time high despite being suppressed by lower patient volumes treated by our providers."
• "It looked to us as though the whole industry sort of took its foot off the gas for a minute as it waited for clarity on proposed reimbursement changes and that concerns about compliance and audits led practitioners to adopt, at the margin, a cautious wait and see attitude on initiating a number of kinds of advanced wound care regimens for patients."
• "On Friday, October 31, 2025, after close of business, CMS published its final rule for 2026 Medicare physician fees. 2026 reimbursement for the 97610 code was in line with our expectations of a slight increase versus 2025 and was not affected by cuts to other modalities."
• "Times of sudden change can make for bumpy periods, and while its still very early to assess industry reaction to the new CMS rule, our sense is that any certainty is better than such large uncertainty and that the market will now move to adapt."
• "Were seeing a lot of inbound interest from customers and distribution partners and our sales pipeline remains robust. This continues to make us highly optimistic about the future."

Industry Context

The wound care industry experienced headwinds due to uncertainty surrounding proposed reimbursement changes for certain modalities like skin substitutes/allografts. This led to a cautious "wait and see" approach among practitioners, impacting patient volumes and advanced wound care initiations. However, the recent publication of CMS's final rule for 2026 Medicare physician fees, which confirmed a slight increase for the 97610 code (relevant to Sanuwave's products) and no negative impact from cuts to other modalities, is expected to bring much-needed clarity and allow the market to adapt. This certainty is anticipated to stimulate renewed activity and interest in advanced wound care solutions.

Comparison to Industry Standards

• The filing mentions "difficult comparison of Q3 last year when a large order drove 89% year on year growth" for Sanuwave, indicating that while 22% growth this quarter is strong, it's against a high base.
• The CEO notes that "the whole industry sort of took its foot off the gas for a minute as it waited for clarity on proposed reimbursement changes," suggesting Sanuwave's experience of suppressed patient volumes and cautious practitioners was an industry-wide trend.
• The positive outcome of the CMS final rule for the 97610 code, which was "in line with our expectations of a slight increase versus 2025 and was not affected by cuts to other modalities," positions Sanuwave favorably compared to other wound care companies whose modalities might have faced cuts.

Stakeholder Impact

• Shareholders: Positive impact from record revenues, improved net income (though partially non-cash), increased Adjusted EBITDA, and positive future guidance. The reduction in stockholders' deficit is also positive.
• Customers/Providers: Benefit from clarity on CMS reimbursement for the 97610 code, which supports the use of Sanuwave's UltraMist products.
• Employees: Stock-based compensation costs were $1.4 million in Q3 2025, indicating ongoing equity incentives.
• Creditors: The company refinanced debt, taking on a new secured term loan and revolving credit facility while paying off a significant note payable, which could alter the risk profile for different creditors.

Next Steps

• A business update via conference call occurred on November 7, 2025, at 8:30 am EST.
• The market is expected to adapt to the new CMS rule for 2026 Medicare physician fees.
• The company will continue to pursue inbound interest from customers and distribution partners.

Key Dates

Recommendation

Sanuwave Health delivered record quarterly revenues and strong year-over-year growth of 22%, demonstrating robust operational performance in its core UltraMist system and consumables sales, despite industry headwinds. The significant improvement in net income and Adjusted EBITDA, coupled with positive revenue guidance for Q4 and full year 2025, indicates continued momentum. Crucially, the recent clarity from CMS regarding 2026 Medicare reimbursement for the 97610 code, which is favorable to Sanuwave's products, removes a key industry uncertainty and is expected to drive further market adaptation and demand. While the operating income was impacted by stock-based compensation and net income benefited from non-cash gains and a one-time patent sale, the underlying business fundamentals and future outlook are strong, making it an an attractive investment.

Keywords

wound care, medical devices, UltraMist, shockwave therapy, FDA approved, financial results, Q3 2025, revenue growth, gross margin, Adjusted EBITDA, CMS reimbursement, healthcare industry, Sanuwave Health